Perhaps the most relevant question, given the topic here, is why PYC hasn't been snapped up at a bargain basement price? If the technology was working as well as management keeps saying, paying a significant premium over current market cap would still be small change for one of the medium - large pharma. Unless PYC has been able to build in some sort of "poison pill" arrangements into its current agreements, making it difficult for it to be taken out (and why you'd do that, God only knows!), one can only speculate that the technology hasn't yet rerached the "compelling stage" in terms of being able to make real drug candidates. Thoughts?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.005(0.34%) |
Mkt cap ! $842.8M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.46 | $1.40 | $451.6K | 315.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10001 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 3114 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |